Nanoparticles for lung cancer pass next test

April 11, 2018, Thomas Jefferson University
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors. Jefferson College of Pharmacy researchers are developing a new treatment approach based on nanotechnology that was recently shown to be effective in mouse models of the disease. The research was published in the journal Molecular Pharmaceutics.

The nanoparticles were designed to deliver a molecule that's been shown to stall growth and may make tumors more susceptible to chemotherapy. The molecule, called microRNA 29b, would be ineffective if delivered by injection alone, as it quickly becomes degraded in the bloodstream or picked up and removed by immune cells.

To bypass these limitations, Sunday Shoyele, PhD, Associate Professor in the Department of Pharmaceutical Sciences at Jefferson (Philadelphia University + Thomas Jefferson University) and colleagues, developed a nanoparticle comprised of four parts. First, Dr. Shoyele included part of a human antibody, immunoglobulin G (IgG), to cloak the particle from the immune system. Second, the research team added the MUC1 antigen, which acts like a navigation system guiding the to the MUC1-covered lung tumors. Finally, the therapeutic payload, microRNA-29b, along with the other two components are glued together using a sticky polymer called poloxamer-188.

Dr. Shoyele and colleagues showed that these components formed a spherical nanoparticle capable of properly finding the tumors and shrinking the tumors in mouse models of the disease. "This work extends our previous work demonstrating that these particles were effective in shrinking tumor tissue in a petri dish. Here we show that they are also effective in a more complex living system," said Dr. Shoyele.

Additional tests are needed before the technology is ready for testing in human clinical trials. Dr. Shoyele plans to continue the research with comprehensive toxicity tests and scaling the nanoparticle manufacturing process for clinical trials.

Explore further: Researchers develop novel immunotherapy to target colorectal cancer

More information: Maryna Perepelyuk et al, Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer, Molecular Pharmaceutics (2018). DOI: 10.1021/acs.molpharmaceut.7b00900

Related Stories

Nano packages for anti-cancer drug delivery

March 18, 2015

Cancer stem cells are resistant to chemotherapy and consequently tend to remain in the body even after a course of treatment has finished, where they can often trigger cancer recurrence or metastasis. A new study by researchers ...

Recommended for you

Atomic-scale ping-pong

June 20, 2018

New experiments by researchers at the National Graphene Institute at the University of Manchester have shed more light on the gas flow through tiny, angstrom-sized channels with atomically flat walls.

Chameleon-inspired nanolaser changes colors

June 20, 2018

As a chameleon shifts its color from turquoise to pink to orange to green, nature's design principles are at play. Complex nano-mechanics are quietly and effortlessly working to camouflage the lizard's skin to match its environment.

Method could help boost large scale production of graphene

June 19, 2018

The measure by which any conductor is judged is how easily, and speedily, electrons can move through it. On this point, graphene is one of the most promising materials for a breathtaking array of applications. However, its ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.